200 million children live with a rare disease, but only 5% of those diseases have treatments available. ACC Bioscience Incubator member company Everlum Bio has set out to change these stats by developing proof-of-concept therapeutics for rare genetic diseases. Since moving into the Bioscience Incubator in May, they have already begun to give hope to families of children like Rose and their work was recently featured in Endpoints News.